ABL

Executive Summary

ABL is a French contract development and manufacturing organization (CDMO) based in Lyon, founded in 2006. The company provides comprehensive services for the development and production of biologics, cell therapies, and viral vectors, supporting biotech and pharmaceutical clients from pre-clinical stages through to commercial manufacturing. With the increasing demand for biologics and advanced therapies, ABL is well-positioned in the European CDMO market, leveraging its expertise in viral vectors and cell therapy manufacturing to capture growth opportunities. As a private company with no disclosed financials, ABL's performance is tied to its ability to secure new client contracts and expand capacity. The biologics outsourcing trend, particularly for cell and gene therapies, bodes well for the company's outlook. Upcoming catalysts could include announcements of capacity expansions, strategic partnerships, or regulatory milestones for client products. With a solid foundation and niche focus, ABL is poised to benefit from the growing biologics manufacturing market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new manufacturing capacity expansion (e.g., additional viral vector suites)70% success
• H2 2026Strategic partnership or long-term supply agreement with a major biopharma company60% success
• Q4 2026Regulatory approval of a client's cell or gene therapy product manufactured by ABL50% success